A Challenge to the Standard Cosmological Model Secrest, Nathan J.; von Hausegger, Sebastian; Rameez, Mohamed ...
Astrophysical journal. Letters,
10/2022, Letnik:
937, Številka:
2
Journal Article
Recenzirano
Odprti dostop
Abstract
We present the first joint analysis of catalogs of radio galaxies and quasars to determine whether their sky distribution is consistent with the standard ΛCDM model of cosmology. This model ...is based on the cosmological principle, which asserts that the universe is statistically isotropic and homogeneous on large scales, so the observed dipole anisotropy in the cosmic microwave background (CMB) must be attributed to our local peculiar motion. We test the null hypothesis that there is a dipole anisotropy in the sky distribution of radio galaxies and quasars consistent with the motion inferred from the CMB, as is expected for cosmologically distant sources. Our two samples, constructed respectively from the NRAO VLA Sky Survey and the Wide-field Infrared Survey Explorer, are systematically independent and have no shared objects. Using a completely general statistic that accounts for correlation between the found dipole amplitude and its directional offset from the CMB dipole, the null hypothesis is independently rejected by the radio galaxy and quasar samples with
p
-values of 8.9 × 10
−3
and 1.2 × 10
−5
, respectively, corresponding to 2.6
σ
and 4.4
σ
significance. The joint significance, using sample-size-weighted
Z
-scores, is 5.1
σ
. We show that the radio galaxy and quasar dipoles are consistent with each other and find no evidence for any frequency dependence of the amplitude. The consistency of the two dipoles improves if we boost to the CMB frame assuming its dipole to be fully kinematic, suggesting that cosmologically distant radio galaxies and quasars may have an intrinsic anisotropy in this frame.
Using 8.4 yr of photometry from the AllWISE/NEOWISE multi-epoch catalogs, we compare the mid-infrared variability properties of a sample of 2197 dwarf galaxies (M < 2 × 109 h−2 M☉) to a sample of ...6591 more massive galaxies (M ≥ 1010 h−2 M☉) matched in mid-infrared apparent magnitude. We find only two dwarf galaxies with mid-infrared variability, a factor of ∼10 less frequent than the more massive galaxies (p = 6 × 10−6), consistent with previous findings of optical variability in low-mass and dwarf galaxies using data with a similar baseline and cadence. Within the more massive control galaxy population, we see no evidence for a stellar mass dependence of mid-infrared variability, suggesting that this apparent reduction in the frequency of variable objects occurs below a stellar mass of ∼1010 h−2 M☉. Compared to the more massive galaxies, active galactic nuclei (AGNs) selected in dwarf galaxies using either their mid-infrared color or optical emission-line classification are systematically missed by variability selection. Our results suggest, in agreement with previous optical studies at similar cadence, that variability selection of AGNs in dwarf galaxies is ineffective unless higher-cadence data are used.
A direct consequence of hierarchical galaxy formation is the existence of dual supermassive black holes, which may be preferentially triggered as active galactic nuclei (AGNs) during galaxy mergers. ...Despite decades of searching, however, dual AGNs are extremely rare, and most have been discovered serendipitously. Using the all-sky WISE survey, we identified a population of over 100 morphologically identified interacting galaxies or mergers that display red mid-infrared colors often associated in extragalactic sources with powerful AGNs. The vast majority of these advanced mergers are optically classified as star-forming galaxies, which suggests that they may represent an obscured population of AGNs that cannot be found through optical studies. In this work, we present Chandra/ACIS observations and near-infrared spectra with the Large Binocular Telescope of six advanced mergers with projected pair separations less than ∼10 kpc. The combined X-ray, near-infrared, and mid-infrared properties of these mergers provide confirmation that four out of the six mergers host at least one AGN, with four of the mergers possibly hosting dual AGNs with projected separations less than ∼10 kpc, despite showing no firm evidence for AGNs based on optical spectroscopic studies. Our results demonstrate that (1) optical studies miss a significant fraction of single and dual AGNs in advanced mergers, and (2) mid-infrared pre-selection is extremely effective in identifying dual AGN candidates in late-stage mergers. Our multi-wavelength observations suggest that the buried AGNs in these mergers are highly absorbed, with intrinsic column densities in excess of cm−2, consistent with hydrodynamic simulations.
ABSTRACT
Galaxy mergers are predicted to trigger accretion on to the central supermassive black holes, with the highest rates occurring during final coalescence. Previously, we have shown elevated ...rates of both optical and mid-IR selected active galactic nuclei (AGNs) in post-mergers, but to date the prevalence of X-ray AGNs has not been examined in the same systematic way. We present XMM–Newton data of 43 post-merger galaxies selected from the Sloan Digital Sky Survey along with 430 non-interacting control galaxies matched in stellar mass, redshift, and environment in order to test for an excess of hard X-ray (2–10 keV) emission in post-mergers attributable to triggered AGNs. We find two X-ray detections in the post-mergers ($4.7^{+9.3}_{-3.8}{{\ \rm per\ cent}}$) and nine in the controls ($2.1^{+1.5}_{-1.0}{{\ \rm per\ cent}}$), an excess of $2.22^{+4.44}_{-2.22}$, where the confidence intervals are 90 per cent. While, we therefore do not find statistically significant evidence for an X-ray AGN excess in post-mergers (p = 0.26), we find a factor of ∼17 excess of mid-IR AGNs in our sample, consistent with the past work and inconsistent with the observed X-ray excess (p = 2.7 × 10−4). Dominant, luminous AGNs are therefore more frequent in post-mergers, and the lack of a comparable excess of 2–10 keV X-ray AGNs suggests that AGNs in post-mergers are more likely to be heavily obscured. Our results are consistent with the post-merger stage being characterized by enhanced AGN fueling, heavy AGN obscuration, and more intrinsically luminous AGN, in line with theoretical predictions.
Abstract
Making use of strong correlations between closely separated multiple or double sources and photometric and astrometric metadata in Gaia Early Data Release 3 (EDR3), we generate a catalog of ...candidate double- and multiply imaged lensed quasars and active galactic nuclei (AGNs), comprising 3140 systems. It includes two partially overlapping parts: a sample of distant (redshifts mostly greater than 1) sources with perturbed data; and systems that have been resolved into separate components by Gaia at separations less than 2″. For the first part, which is roughly one-third of the published catalog, we synthesized 0.617 million redshifts using multiple machine-learning prediction and classification methods, using independent photometric and astrometric data from Gaia EDR3 and the Wide-field Infrared Survey Explorer, with accurate spectroscopic redshifts from the Sloan Digital Sky Survey (SDSS) as a training set. Using these synthetic redshifts, we estimate a 4.9% rate of interlopers with spectroscopic redshifts below 1 in this part of the catalog. Unresolved candidate double and dual AGNs and quasars are selected as sources with a marginally high BP/RP excess factor (
phot
_
bp
_
rp
_
excess
_
factor
), which is sensitive to source extent, limiting our search to high-redshift quasars. For the second part of the catalog, additional filters on measured parallax and near-neighbor statistics are applied to diminish the propagation of the remaining stellar contaminants. The estimated rate of the positives (double or multiple sources) is 98%, and the estimated rate of dual (physically related) quasars is greater than 54%. A few dozen serendipitously found objects of interest are discussed in more detail, including known and new lensed images, planetary nebulae, young IR stars of peculiar morphology, and quasars with catastrophic redshift errors in SDSS.
Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment ...of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1.
We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment sPGA score of 0 clear or 1 minimal psoriasis) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12.
In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease.
In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known. (Funded by Eli Lilly; UNCOVER-1, UNCOVER-2, and UNCOVER-3 ClinicalTrials.gov numbers NCT01474512, NCT01597245, and NCT01646177, respectively.).
Summary Background Ixekizumab is a humanised monoclonal antibody against the proinflammatory cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or etanercept to ...assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. Methods In two prospective, double-blind, multicentre, phase 3 studies (UNCOVER-2 and UNCOVER-3), eligible patients were aged 18 years or older, had a confirmed diagnosis of chronic plaque psoriasis at least 6 months before baseline (randomisation), 10% or greater body-surface area involvement at both screening and baseline visits, at least a moderate clinical severity as measured by a static physician global assessment (sPGA) score of 3 or more, and a psoriasis area and severity index (PASI) score of 12. Participants were randomly assigned (1:2:2:2) by computer-generated random sequence with an interactive voice response system to receive subcutaneous placebo, etanercept (50 mg twice weekly), or one injection of 80 mg ixekizumab every 2 weeks, or every 4 weeks after a 160 mg starting dose. Blinding was maintained with a double-dummy design. Coprimary efficacy endpoints were proportions of patients achieving sPGA score 0 or 1 and 75% or greater improvement in PASI at week 12. Analysis was by intention to treat. These trials are registered with ClinicalTrials.gov , numbers NCT01597245 and NCT01646177. Findings Between May 30, 2012, and Dec 30, 2013, 1224 patients in UNCOVER-2 were randomly assigned to receive subcutaneous placebo (n=168), etanercept (n=358), or ixekizumab every 2 weeks (n=351) or every 4 weeks (n=347); between Aug 11, 2012, and Feb 27, 2014, 1346 patients in UNCOVER-3 were randomly assigned to receive placebo (n=193), etanercept (n=382), ixekizumab every 2 weeks (n=385), or ixekizumab every 4 weeks (n=386). At week 12, both primary endpoints were met in both studies. For UNCOVER-2 and UNCOVER-3 respectively, in the ixekizumab every 2 weeks group, PASI 75 was achieved by 315 (response rate 89·7%; effect size 87·4% (97·5% CI 82·9–91·8) vs placebo; 48·1% (41·2–55·0) vs etanercept) and 336 (87·3%; 80·0% (74·4–85·7) vs placebo; 33·9% (27·0–40·7) vs etanercept) patients; in the ixekizumab every 4 weeks group, by 269 (77·5%; 75·1% (69·5–80·8) vs placebo; 35·9% (28·2–43·6) vs etanercept) and 325 (84·2%; 76·9% (71·0–82·8) vs placebo; 30·8% (23·7–37·9) vs etanercept) patients; in the placebo group, by four (2·4%) and 14 (7·3%) patients; and in the etanercept group by 149 (41·6%) and 204 (53·4%) patients (all p<0·0001 vs placebo or etanercept). In the ixekizumab every 2 weeks group, sPGA 0/1 was achieved by 292 (response rate 83·2%; effect size 80·8% (97·5% CI 75·6–86·0) vs placebo; 47·2% (39·9–54·4) vs etanercept) and 310 (80·5%; 73·8% (67·7–79·9) vs placebo; 38·9% (31·7–46·1) vs etanercept) patients; in the ixekizumab every 4 weeks group by 253 (72·9%; 70·5% (64·6–76·5) vs placebo; 36·9% (29·1–44·7) vs etanercept) and 291 (75·4%; 68·7% (62·3–75·0) vs placebo; 33·8% (26·3–41·3) vs etanercept) patients; in the placebo group by four (2·4%) and 13 (6·7%) patients; and in the etanercept group by 129 (36·0%) and 159 (41·6%) patients (all p<0·0001 vs placebo or etanercept). In combined studies, serious adverse events were reported in 14 (1·9%) of 734 patients given ixekizumab every 2 weeks, 14 (1·9%) of 729 given ixekizumab every 4 weeks, seven (1·9%) of 360 given placebo, and 14 (1·9%) of 739 given etanercept; no deaths were noted. Interpretation Both ixekizumab dose regimens had greater efficacy than placebo and etanercept over 12 weeks in two independent studies. These studies show that selectively neutralising interleukin 17A with a high affinity antibody potentially gives patients with psoriasis a new and effective biological therapy option. Funding Eli Lilly and Co.
Radio-optical Reference Catalog, Version 1 Makarov, Valeri V.; Johnson, Megan C.; Secrest, Nathan J.
The Astronomical journal,
07/2023, Letnik:
166, Številka:
1
Journal Article
Recenzirano
Odprti dostop
Abstract
The fundamental celestial reference frame (CRF) is based on two catalogs of astrometric positions: the third realization of the International Celestial Reference Frame (ICRF3), and the much ...larger Gaia CRF, built from the third data release (DR3). The objects in common between these two catalogs are mostly distant AGNs and quasars that are both sufficiently optically bright for Gaia and radio loud for the VLBI. This limited collection of reference objects is crucially important for the mutual alignment of the two CRFs and the maintenance of all of the other frames and coordinate systems branching from the ICRF. In this paper, we show that the three components of ICRF3 (
S/X, K
, and
X/Ka
band catalogs) have significantly different sky-correlated vector fields of position offsets with respect to Gaia DR3. When iteratively expanded in the vector spherical harmonics up to degree 4 on a carefully vetted set of common sources, each of these components includes several statistically significant terms. The median sky-correlated offsets from the Gaia positions are found to be 56
μ
as for the
S/X
, 100
μ
as for the
K
, and 324
μ
as for the
X/Ka
catalogs. The weighted mean vector field is subtracted from the Gaia reference positions, while the deviations from that field are added to each of the ICRF3 components. The corrected positions from each of the four input catalogs are combined into a single weighted mean catalog, which we propose to be the current most accurate realization of an inertial radio-optical CRF.
Observations and theoretical simulations suggest that a significant fraction of merger-triggered accretion onto supermassive black holes is highly obscured, particularly in late-stage galaxy mergers, ...when the black hole is expected to grow most rapidly. Starting with the Wide-Field Infrared Survey Explorer all-sky survey, we identified a population of galaxies whose morphologies suggest ongoing interaction and which exhibit red mid-infrared colors often associated with powerful active galactic nuclei (AGNs). In a follow-up to our pilot study, we now present Chandra/ACIS and XMM-Newton X-ray observations for the full sample of the brightest 15 IR-preselected mergers. All mergers reveal at least one nuclear X-ray source, with 8 out of 15 systems exhibiting dual nuclear X-ray sources, highly suggestive of single and dual AGNs. Combining these X-ray results with optical line ratios and with near-IR coronal emission line diagnostics, obtained with the near-IR spectrographs on the Large Binocular Telescope, we confirm that 13 out of the 15 mergers host AGNs, two of which host dual AGNs. Several of these AGNs are not detected in the optical. All X-ray sources appear X-ray weak relative to their mid-infrared continuum, and of the nine X-ray sources with sufficient counts for spectral analysis, eight reveal strong evidence of high absorption with column densities of NH 1023 cm−2. These observations demonstrate that a significant population of single and dual AGNs are missed by optical studies, due to high absorption, adding to the growing body of evidence that the epoch of peak black hole growth in mergers occurs in a highly obscured phase.
Abstract
We present the discovery of a gravitationally lensed dust-reddened QSO at
z
= 2.517, identified in a survey for QSOs by infrared selection. Hubble Space Telescope imaging reveals a quadruply ...lensed system in a cusp configuration, with a maximum image separation of ∼1.″8. We find that, compared to the central image of the cusp, the neighboring brightest image is anomalous by a factor of ∼7–10, which is the largest flux anomaly measured to date in a lensed QSO. Incorporating high-resolution Very Large Array radio imaging and submillimeter imaging with the Atacama Large Millimeter/submillimeter Array, we conclude that a low-mass perturber is the most likely explanation for the anomaly. The optical through near-infrared spectrum reveals that the QSO is moderately reddened with
E
(
B
−
V
) ≃ 0.7–0.9. We see an upturn in the ultraviolet spectrum due to ∼1% of the intrinsic emission being leaked back into the line of sight, which suggests that the reddening is intrinsic and not due to the lens. The QSO may have an Eddington ratio as high as
L
/
L
Edd
≈ 0.2. Consistent with previous red QSO samples, this source exhibits outflows in its spectrum, as well as morphological properties suggestive of it being in a merger-driven transitional phase. We find a host galaxy stellar mass of
log
M
⋆
/
M
⊙
=
11.4
, which is higher than the local
M
BH
versus
M
⋆
relation but consistent with other high-redshift QSOs. When demagnified, this QSO is at the knee of the luminosity function, allowing for the detailed study of a more typical moderate-luminosity infrared-selected QSO at high redshift.
PDF
